Induction therapy with interleukin-2 receptor antagonist after intestinal transplantation is associated with reduced acute cellular rejection and improved renal function

Transplantation Proceedings

Volumn 36, Issue 2, 2004, Pages 331-332

  Farmer, D G ^a,b   McDiarmid, S V ^a   Edelstein, S ^a   Renz, J F ^a   Hisatake, G ^a   Cortina, G ^a   Fondevila, C ^a   Correa, M ^a   Rhodes, S ^a   Zafar, A ^a   Chavez, Y ^a   Yersiz, H ^a   Busuttil, R W ^a  

^a UCLA MEDICAL CENTER   (United States)

^b CHS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BASILIXIMAB; CREATINE KINASE; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY;

ACUTE GRAFT REJECTION; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DATA BASE; DRUG EFFICACY; FEMALE; HUMAN; IMMUNOTHERAPY; INFORMATION PROCESSING; INTESTINE TRANSPLANTATION; KIDNEY FUNCTION; MALE; MEDICAL RECORD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SURVIVAL;

CHILD; CHILD, PRESCHOOL; GLOMERULAR FILTRATION RATE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MUROMONAB-CD3; RECEPTORS, INTERLEUKIN-2; RETROSPECTIVE STUDIES;

EID: 12144290019     PISSN: 00411345     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transproceed.2004.01.099     Document Type: Conference Paper

References (5)

1. Abu-Elmagd K., Reyes J., Bond G., et al. Clinical intestinal transplantation a decade of experience at a single center. Ann Surg. 234:2001;404.
2. Langnas A., Chinnakotla S., Sudan D., et al. Intestinal transplantation at the University of Nebraska Medical Center: 1990-2001. Transplant Proc. 34:2002;958.
3. Abu-Elmagd K., Fung J., McGhee W., et al. The efficacy of daclizumab for intestinal transplantation preliminary report. Transplant Proc. 32:2000;1195.
4. Carreno M.R., Kato T., Weppler D., et al. Induction therapy with daclizumab as part of the immunosuppressive regimen in human small bowel and multiorgan transplants. Transplant Proc. 33:2001;1015.
5. Sudan D.L., Chinnakotla S., Horslen S., et al. Basiliximab decreases the incidence of acute rejection after intestinal transplantation. Transplant Proc. 34:2002;940.